Filing Flows › Bio-Rad Laboratories (BIO) › How it makes money
How Bio-Rad Laboratories (BIO) makes money
Bio-Rad Laboratories (BIO) made $656M of revenue in the third quarter 2026 (Q3 2026), +0.5% from a year earlier. Clinical Diagnostics brought in $402M (61%); Life Science brought in $255M (39%).
Drawing the Sankey…
Revenue by segment, Q3 2026
| Segment | Revenue | Share | Q/Q | Y/Y |
|---|---|---|---|---|
| Clinical Diagnostics | $402M | 61.2% | +0.7% | +3% |
| Life Science | $255M | 38.8% | +1% | -3% |
Where each dollar of revenue goes
| Line | Q3 2026 | % of revenue |
|---|---|---|
| Revenue | $656M | 100.0% |
| Income tax | $80.1M | 12.2% |
| Operating cash flow | $96.4M | 14.7% |
| Free cash flow | $65.2M | 9.9% |
Revenue, quarter by quarter
| Quarter | Revenue | Y/Y |
|---|---|---|
| Q3 2026 | $656M | +0.5% |
| Q2 2026 | $651M | -0.1% |
| Q1 2026 | $592M | +1% |
| Q4 2025 | $693M | +4% |
| Q3 2025 | $653M | +0.5% |
| Q2 2025 | $652M | +2% |
| Q1 2025 | $585M | -4% |
From Bio-Rad Laboratories' 10-Q filed Nov 4, 2026 (on EDGAR).
Questions
How does Bio-Rad Laboratories make money?
Bio-Rad Laboratories (BIO) made $656M of revenue in the third quarter 2026 (Q3 2026), +0.5% from a year earlier. Clinical Diagnostics brought in $402M (61%); Life Science brought in $255M (39%).
What is Bio-Rad Laboratories' biggest business?
Clinical Diagnostics: $402M in the third quarter 2026, 61% of revenue, +3% from a year earlier.
Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.